Use case
Biotech investors tracking a company's clinical or regulatory catalyst dates open the catalyst calendar and map each date back to the original SEC filing sentence to verify the event exists and how it is worded.
Investors currently manually check SEC filings, financial calendars and press releases, assembling catalyst timelines themselves and verifying each entry.
Public material only describes a calendar with source links and shows no user complaints; inferred from the task structure, the pain is that catalyst dates are scattered across earnings reports, 8-Ks and news, forcing repeated searching between calendar and filings, and inconsistent dates make it hard to judge which is trustworthy.
xOcto's call
Demand is evidenced
Trend: vertical financial information is moving from aggregated calendars toward sentence-level verification traceable to original disclosures. Entry: start with the narrow biotech investor research audience and sell the catalyst calendar with source traceability as report-based or subscription delivery rather than another general finance calendar.
Reason to use it
Why users would choose it
Inference: versus manually searching between calendar and filings, linking each date directly to the SEC sentence removes one retrieval step and makes dates traceable, so biotech investors verifying catalyst authenticity before a position or event would choose it; public material has no user feedback confirming this.
Where the easy answer breaks down
The tension worth following
An English validation note will follow from the public evidence.
If this is your job
Worth trying. Inference: versus manually searching between calendar and filings, linking each date directly to the SEC sentence removes one retrieval step and makes dates traceable, so biotech investors verifying catalyst authenticity before a position or event would choose it; public material has no user feedback confirming this.
Entry and what to borrow
Trend: vertical financial information is moving from aggregated calendars toward sentence-level verification traceable to original disclosures. Entry: start with the narrow biotech investor research audience and sell the catalyst calendar with source traceability as report-based or subscription delivery rather than another general finance calendar.